vpcat project
play

VPCAT Project Sarah Majercik, MD, MBA, FACS 7 April 2017 Venous - PowerPoint PPT Presentation

VPCAT Project Sarah Majercik, MD, MBA, FACS 7 April 2017 Venous Thromboembolism Screening in the Trauma Population A Randomized Vanguard Trial VTE is a major problem after trauma In patients who survive >72 hours after traumatic


  1. VPCAT Project Sarah Majercik, MD, MBA, FACS 7 April 2017

  2. Venous Thromboembolism Screening in the Trauma Population — A Randomized Vanguard Trial

  3. VTE is a major problem after trauma • In patients who survive >72 hours after traumatic insult, VTE is a main cause of death • Reported incidence in trauma patients: • DVT 11.8%-65% • PE 1.5%-2.3% • IMC rate • DVT 3% • PE 0.6%

  4. Why is VTE an issue in trauma patients?

  5. Why is VTE an issue in trauma patients? • Traumatic injury causes direct or indirect endothelial injury, activates tissue factor, platelet aggregation, propagating the coagulation cascade, e.g. TRAUMA • Trauma patients are often immobile and need surgical procedures, e.g. STASIS • Acute phase reactants from trauma itself and from postoperative state, e.g. HYPERCOAGULABILITY

  6. Background • Venous Thromboembolism (VTE) is responsible for a $69billion economic impact annually in the US • VTE is a major cause of late morbidity and mortality in trauma patients • At the time of VTE diagnosis, most patients are already receiving standard chemoprophylaxis • VTE will never be a “never” event in trauma, no matter what CMS would like to tell us — it is on the HAC score checklist

  7. Background Therapy guidelines just published in 2016

  8. Background Most Recent Prevention Guidelines are from 2012

  9. Current recommendation for major trauma Routine surveillance NOT patients is NO recommended! surveillance

  10. VTE surveillance in trauma patients • Quality of evidence to support this recommendation is poor • Mostly retrospective • Often conflicting

  11. Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010 Apr;38(4 Suppl):S502-9. Investigators Haut ER, Schneider EB, Patel A, Streiff MB, Haider AH, Stevens KA, Chang DC, Neal ML, Hoeft C, Nathens AB, Cornwell EE 3 rd , Pronovost PJ, Efron DT. Duplex ultrasound screening for deep vein thrombosis in are interested asymptomatic trauma patients: a survey of individual trauma surgeon opinions and current trauma center practices. J Trauma. 2011 Jan;70(1):27-33. in this topic, Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ. Antithrombotic Therapy and Prevention but no one has of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines CHEST 2012; 141(2)(Suppl):7S – 47S. successfully Adams RC, Hamrick M, Berenguer C, Senkowski C, Ochsner MG. Four Years of an Aggressive Prophylaxis and Screening Protocol for Venous Thromboembolism in a Large Trauma Population. J Trauma. 2008 executed a Aug;65(2):300-6. good quality Napolitano LM, Garlapati VS, Heard SO, Silva WE, Cutler BS, O’Neill AM, Anderson FA Jr, Wheeler HB. Asymptomatic deep venous thrombosis in the trauma patient: is an aggressive screening protocol study! justified? J Trauma. 1995 Oct;39(4):651-7. Malhotra AK, Goldberg SR, McLay L, Martin NR, Wolfe LG, Levy MM, Khiatani V, Borchers TC, Duane TM, Aboutanos MB, Ivatury RR. DVT Surveillance Program in the ICU: Analysis of Cost-Effectiveness. PLoS One. 2014 Sep 30;9(9):e106793 . doi: 10.1371/journal.pone.0106793. Cipolle MD, Wojcik R, Seislove E, Wasser TE, Pasquale MD. The role of surveillance duplex scanning in preventing venous thromboembolism in trauma patients. J Trauma. 2002 Mar;52(3):453-62. Schwarcz TH, Quick RC, Minion DJ, Kearney PA, Kwolek CJ, Endean ED. Enoxaparin treatment in high-risk trauma patients limits the utility of surveillance venous duplex scanning. J Vasc Surg. 2001 Sep;34(3):447- 52

  12. • Based on this grade 2C (mostly retrospective) evidence, most trauma centers in the United States choose not to perform surveillance on trauma patients • Intermountain Medical Center has traditionally performed Duplex Ultrasound surveillance on high risk trauma patients • Consequently, our VTE rate (mostly asymptomatic DVT) is higher than has been deemed “acceptable”

  13. There are currently ZERO prospective, randomized studies that specifically examine VTE surveillance in the trauma patient

  14. Why is this important? • Asymptomatic lower extremity DVT diagnosis is not really the point — preventing fatal PE is. • Hospitals under pressure to decrease DVT rate • If we stop looking, our rate will decrease … • Is this the best patient care?

  15. HYPOTHESIS: High risk trauma patients who undergo scheduled ultrasound surveillance for lower extremity DVT will have a lower rate of: • Symptomatic DVT • DVT propagation • Symptomatic or fatal PE

  16. Specific Aims: 1. Determine the rate of VTE (DVT and PE) in high-risk trauma patients who have surveillance for lower extremity DVT versus those who do not have surveillance 2. Determine the rate of DVT propagation to the popliteal vein or higher by 14 days after discharge in high-risk trauma patients found to have isolated distal DVT

  17. Outcome Measures: 1. Asymptomatic lower extremity DVT identified during hospitalization (in surveillance group) 2. Symptomatic DVT identified during hospitalization and at 90 days post discharge 3. Symptomatic DVT propagation from calf to proximal veins at 14 days post-discharge 4. Symptomatic/fatal PE identified during hospitalization and at 90 days post-discharge 5. Major bleeding episodes 6. Composite outcome of proximal DVT plus major bleeding episodes 7. All cause mortality at 90 days post-discharge

  18. Study Design: 1. Prospective, randomized trial — surveillance at days 1, 3, 7, weekly vs. no surveillance 2. Exception from informed consent approved by IRB 3. All high risk trauma patients enrolled

  19. Inclusion Criteria: 1. Inpatient on IMC trauma surgery service, admitted within 24 hours of injury 2. Age ≥ 18 3. Meets definition of high-risk for VTE

  20. Exclusion Criteria: 1. Age <18 2. Pregnancy 3. Prisoners 4. Life expectancy <30 days 5. Known hypercoagulable state, including Factor V Leiden, Protein C and S deficiencies, dysfibrogenemia, active cancer, antiphospholipid antibody syndrome

  21. Data Analysis: • Used historic baseline of composite outcome of major bleeding plus proximal DVT on trauma service to conduct power analysis

  22. Current Status: • Enrolling patients • Estimate 12-16 months to complete enrollment • Relatively low ISS and homogeneous population of IMC trauma service will be a limitation

  23. Future Plans • Results of this vanguard trial will pave the way for a larger, likely multi-institutional trial • Will answer an important question that will impact trauma patients everywhere — far beyond just Intermoutain

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend